Deal Snapshot: Building on a 2021 tie-up between Takeda and the Paragon start-up, Evozyne will seek novel protein sequences for inclusion in gene therapies for rare disease indications.

While a cloud hangs over the future of its CD19-targeting allogeneic candidate, Allogene points to preclinical potential of superior efficacy for ALLO-715.

German firm’s antibody-drug conjugates use amanitin payload. Plus deals involving Sanwa Kagaku/Crinetics, Takeda/Code Bio, Taro/Alchemee, Mankind/Dr. Reddy’s and more.

Many industry leaders expect broad progress in the field of RNA technologies following the rapid and successful roll-out of mRNA vaccines against COVID-19 last year. Genetic medicines of various types, emerging platforms for tackling previously “undruggable” targets and the microbiome were among other areas singled out as areas to watch in 2022.